The role of fibrin in tumor metastasis
- 1 November 1992
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 11 (3-4) , 283-290
- https://doi.org/10.1007/bf01307183
Abstract
A volume of data that has accumulated for over a century has suggested that fibrin may facilitate the persistence and progression of malignancy. Techniques that have been developed recently have shown that fibrin is indeed a component of the connective tissue stroma in human malignancy but in only a few tumor types. However, therapeutic intervention studies with drugs that limit thrombin activity or enhance fibrinolysis have shown favorable clinical effects in at least one such tumor type. These favorable findings affirm the concept that cause-and-effect relationships do, in fact, exist between thrombin generation with fibrin formation and tumor progression, and suggest that a rational basis exists for the design of future drug intervention trials that target reactions relevant to specific tumor types. These findings also provide a basis for the design of experiments capable of defining further the role of fibrin in the integrity of these tumor types. Because fibrinogen is found much more commonly than fibrin in the connective tissue of a variety of human malignancies, attention might reassumably be directed to determining the possible contribution of this molecule as well as of fibrin to tumor progression.Keywords
This publication has 59 references indexed in Scilit:
- Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissuesCancer, 1991
- Differential expression of isopeptide bonds Nε(γ-glutamyl) lysine in benign and malignant human breast lesions: An immunohistochemical studyInternational Journal of Cancer, 1991
- Clotting factors in tumour tissueBlood Coagulation & Fibrinolysis, 1990
- Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lungCancer, 1990
- Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1JNCI Journal of the National Cancer Institute, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986
- Fibrin‐enhanced endothelial cell organizationJournal of Cellular Physiology, 1985
- Comparison of fibrin clot retraction with other transformation parameters after hydridization of normal and established cell linesInternational Journal of Cancer, 1983
- Relationship between fibrin clot retraction and tumorigenesis in C3H/10T1/2 cellsInternational Journal of Cancer, 1981